{
    "clinical_study": {
        "@rank": "92280", 
        "arm_group": [
            {
                "arm_group_label": "Tamsulosin plus placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Tamsulosin is a selective \u03b11a-blocker (FlomaxTM), generic since 2009. It is an antagonist of \u03b11-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms."
            }, 
            {
                "arm_group_label": "Tamsulosin plus Tolterodine ER", 
                "arm_group_type": "Experimental", 
                "description": "Tamsulosin is a selective \u03b11a-blocker (FlomaxTM), generic since 2009. It is an antagonist of \u03b11-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.\nTolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether combination therapy with Tolterodine ER\n      and Tamsulosin is more effective than monotherapy with tamsulosin alone in reducing stent\n      symptoms.\n\n      The investigators hope to show that the addition of Tolterodine ER to Tamsulosin will\n      provided added benefits in reducing stent symptoms in patients who have had unilateral\n      placement of a ureteral stent.\n\n      The investigators hypothesize that combination therapy with tamsulosin and tolterodine ER\n      will yield greater symptom relief than tamsulosin alone."
        }, 
        "brief_title": "Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Ureteral Obstruction", 
        "condition_browse": {
            "mesh_term": "Ureteral Obstruction"
        }, 
        "detailed_description": {
            "textblock": "The investigators aim to show that the addition of Tolterodine ER to Tamsulosin will provide\n      added benefits in ameliorating stent related symptoms in patients who have had unilateral\n      placement of a ureteral stent for urolithiasis.  This objective will be assessed by\n      determining the mean difference in the urinary symptom index domain of the Urinary Stent\n      Symptom Questionnaire, which is a validated tool used to assess stent symptoms1.  The\n      investigators felt that a 15% further decrease in the index score in the experimental group,\n      compared to the control group would represent a clinically significant improvement in\n      urinary symptoms, based on the prior studies evaluating lower urinary tract symptoms in\n      patients with stents. The investigators hypothesize that combination therapy with Tamsulosin\n      and Tolterodine ER will yield greater symptom relief than tamsulosin alone."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with unilateral ureteral stent placement for urolithiasis\n\n        Exclusion Criteria:\n\n          1. Pre-existing lower urinary tract symptoms\n\n          2. Active urinary tract infection\n\n          3. Contraindication to anticholinergic medication\n\n               1. Prior hypersensitivity or allergy to tolterodine\n\n               2. Patients with severe hepatic impairment (Child-Pugh Class C)\n\n               3. Patients with uncontrolled close (narrow) angle glaucoma\n\n               4. Patients with urinary retention\n\n          4. Current anticholinergic use\n\n          5. Chronic pelvic pain syndromes (e.g. acute/chronic prostatitis, interstitial cystitis)\n\n          6. Pregnant females\n\n          7. Under 18 years of age\n\n          8. Prior hypersensitivity or allergy to tolterodine\n\n          9. Patients with severe hepatic impairment (Child-Pugh Class C)\n\n         10. Patients with uncontrolled close (narrow) angle glaucoma\n\n         11. Patients with urinary retention\n\n         12. Unable to provide informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "106", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741454", 
            "org_study_id": "2012-0279"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Tamsulosin plus placebo", 
                    "Tamsulosin plus Tolterodine ER"
                ], 
                "description": "0.4 mg by mouth once per day.", 
                "intervention_name": "Tamsulosin", 
                "intervention_type": "Drug", 
                "other_name": "Flomax (TM)"
            }, 
            {
                "arm_group_label": "Tamsulosin plus Tolterodine ER", 
                "description": "4 mg by mouth once a day.", 
                "intervention_name": "Tolterodine ER", 
                "intervention_type": "Drug", 
                "other_name": "Detrol (TM)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholinergic Antagonists", 
                "Tolterodine", 
                "Tamsulosin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Tolterodine", 
            "Tamsulosin", 
            "Ureteral Obstruction"
        ], 
        "lastchanged_date": "December 18, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Sutchin Patel, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Waukegan", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60085"
                    }, 
                    "name": "Vista Medical Center East"
                }, 
                "investigator": {
                    "last_name": "Sutchin Patel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kurtzweil@surgery.wisc.edu", 
                    "last_name": "Nicky Kurtzweil, JD", 
                    "phone": "608-262-9383"
                }, 
                "contact_backup": {
                    "email": "howard@surgery.wisc.edu", 
                    "last_name": "Lauren Howard, MPH", 
                    "phone": "608-265-6648"
                }, 
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University of Wisconsin"
                }, 
                "investigator": {
                    "last_name": "Stephen Nakada, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "David Paolone, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53715"
                    }, 
                    "name": "Meriter Health Services"
                }, 
                "investigator": {
                    "last_name": "David Paolone, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Turki Al-Essawi, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba"
                    }, 
                    "name": "Winnipeg Health Sciences Center"
                }, 
                "investigator": {
                    "last_name": "Turki Al-Essawi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms", 
        "overall_contact": {
            "email": "kurtzweil@surgery.wisc.edu", 
            "last_name": "Nicky Kurtzweil, JD", 
            "phone": "(608) 262-9383"
        }, 
        "overall_contact_backup": {
            "email": "howard@surgery.wisc.edu", 
            "last_name": "Lauren Howard, MPH", 
            "phone": "(608) 265-6648"
        }, 
        "overall_official": {
            "affiliation": "Univeristy of Wisconsin", 
            "last_name": "Stephen Nakada, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Ureteral stent symptom questionnaire score", 
                "measure": "Ureteral stent symptom questionnaire score", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 hours prior to stent insertion"
            }, 
            {
                "description": "Ureteral stent symptom questionnaire score", 
                "measure": "Ureteral stent symptom questionnaire score", 
                "safety_issue": "No", 
                "time_frame": "42-48 hours post-stent insertion"
            }, 
            {
                "description": "Ureteral stent symptom questionnaire score", 
                "measure": "Ureteral stent symptom questionnaire score", 
                "safety_issue": "No", 
                "time_frame": "5 days post-stent insertion"
            }, 
            {
                "description": "Ureteral stent symptom questionnaire score", 
                "measure": "Ureteral stent symptom questionnaire score", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 hours after stent removal.  Removal will occur 5 to 7 days after insertion."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741454"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Wisconsin, Madison", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Wisconsin, Madison", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}